Evidence map›Paper›PMID 36145359›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Novel Effective Fluorinated Benzothiophene-Indole Hybrid Antibacterials against

Marius Seethaler, Tobias Hertlein, Elisa Hopke, Paul Köhling, Knut Ohlsen, Michael Lalk, Andreas Hilgeroth

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marius SeethalerInstitute of Pharmacy, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.ORCID 0000-0003-3486-5531
Tobias HertleinInstitute of Molecular Infection Biology, Julius Maximilians University Würzburg, 97080 Würzburg, Germany.
Elisa HopkeInstitute of Molecular Infection Biology, Julius Maximilians University Würzburg, 97080 Würzburg, Germany.
Paul KöhlingInstitute of Molecular Infection Biology, Julius Maximilians University Würzburg, 97080 Würzburg, Germany.
Knut OhlsenInstitute of Molecular Infection Biology, Julius Maximilians University Würzburg, 97080 Würzburg, Germany.
Michael LalkInstitute of Biochemistry, Ernst Moritz Arndt University Greifswald, 17489 Greifswald, Germany.ORCID 0000-0002-9230-0267
Andreas HilgerothInstitute of Pharmacy, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany.

Funding

Federal Ministry of Education and Research 16GW0198, 16GW0188, 16GW0190
6 · The paper itself

Abstract

Increasing antibacterial drug resistance threatens global health, unfortunately, however, efforts to find novel antibacterial agents have been scaled back by the pharmaceutical industry due to concerns about a poor return on investment. Nevertheless, there is an urgent need to find novel antibacterial compounds to combat antibacterial drug resistance. The synthesis of novel drugs from natural sources is mostly cost-intensive due to those drugs' complicated structures. Therefore, it is necessary to find novel antibacterials by simple synthesis to become more attractive for industrial production. We succeeded in the discovery of four antibacterial compound (sub)classes accessible in a simple one-pot reaction based on fluorinated benzothiophene-indole hybrids. They have been evaluated against various

Indexed as

antibacterial drug resistanceinhibitionstructure activitysubstituentsynthesis

Identifiers

PMID36145359
PMCPMC9502754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.